These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24855350)

  • 1. Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis.
    DiSantostefano RL; Li H; Hinds D; Galkin DV; Rubin DB
    Int J Chron Obstruct Pulmon Dis; 2014; 9():457-68. PubMed ID: 24855350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
    Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trelegy Ellipta--a three-drug inhaler for COPD.
    Med Lett Drugs Ther; 2018 May; 60(1547):86-88. PubMed ID: 29913467
    [No Abstract]   [Full Text] [Related]  

  • 5. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups.
    Bakerly ND; Woodcock A; Collier S; Leather DA; New JP; Crawford J; Harvey C; Vestbo J; Boucot I
    Respir Med; 2019 Feb; 147():58-65. PubMed ID: 30704700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
    Bhatt SP; Dransfield MT; Cockcroft JR; Wang-Jairaj J; Midwinter DA; Rubin DB; Scott-Wilson CA; Crim C
    Int J Chron Obstruct Pulmon Dis; 2017; 12():351-365. PubMed ID: 28176907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of once-daily fluticasone furoate/vilanterol
    Maltais F; Schenkenberger I; Wielders PLML; Ortiz de Saracho J; Chinsky K; Watkins M; Millar V; Crim C
    Ther Adv Respir Dis; 2020; 14():1753466620965145. PubMed ID: 33081606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.
    Malerba M; Nardin M; Santini G; Mores N; Radaeli A; Montuschi P
    Ther Adv Respir Dis; 2018; 12():1753466618760779. PubMed ID: 29537340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial.
    Stone IS; Barnes NC; James WY; Midwinter D; Boubertakh R; Follows R; John L; Petersen SE
    Am J Respir Crit Care Med; 2016 Apr; 193(7):717-26. PubMed ID: 26550687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.
    McKeage K
    Drugs; 2014 Sep; 74(13):1509-22. PubMed ID: 25074268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate.
    Wolthers OD
    Recent Pat Inflamm Allergy Drug Discov; 2015; 9(2):144-50. PubMed ID: 26581314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
    Matera MG; Capuano A; Cazzola M
    Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy.
    Lal C; Strange C
    Int J Chron Obstruct Pulmon Dis; 2017; 12():135-140. PubMed ID: 28115838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD.
    Caramori G; Chung KF; Adcock IM
    Int J Chron Obstruct Pulmon Dis; 2014; 9():249-56. PubMed ID: 24596460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.
    Rodrigo GJ; Neffen H
    Pulm Pharmacol Ther; 2017 Feb; 42():1-6. PubMed ID: 27864038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.
    Papi A; Jones PW; Dalvi PS; McAulay K; McIver T; Dissanayake S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2431-8. PubMed ID: 26648706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis.
    Hinds DR; DiSantostefano RL; Le HV; Pascoe S
    BMJ Open; 2016 Jun; 6(6):e010099. PubMed ID: 27251682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.